The creation of a national database will provide access to solid data on the diagnosis of myeloproliferative neoplasia for patients under 30, giving a true picture of their care. It will also make it possible to identify the biological samples (histological and molecular) available in routine laboratories, enabling teams of researchers and anatomopathologists to (re)perform certain analyses to re-evaluate diagnoses and search for hitherto unknown molecular prognostic factors.
Study Type
OBSERVATIONAL
Enrollment
200
CHU de Brest
Brest, France
Describe the epidemiological characteristics of the study population
Description of MPN subtypes according to age
Time frame: at enrollment
Describe the mutational landscape of these MPNs
Rate of mutations JAK2/CALR/MPL
Time frame: at enrollment
Describe the classical MPN (Myeloproliferative neoplasia) outcomes-1
Incidence of thrombosis
Time frame: At 10 years
Describe the classical MPN outcomes-2
Incidence of myelofibrosis
Time frame: At 10 years
Describe the classical MPN outcomes-3
Incidence of MDS/AML
Time frame: At 10 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.